News

New Atlas23d
First new stroke and UTI drugs in 30 years get FDA approval
Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. More than half of all women will contract this kind of UTI in their lifetime, and almost a third will battle ...
PMLiVE28d
GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections
coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. More than half of women are affected by UTIs, common infections that affect the ...
McKnight's Long-Term Care News28d
FDA approves gepotidacin antibiotic for uncomplicated urinary tract infections
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or uUTIs, successfully and safely. Gepotidacin will be marketed under the bran ...
The Hill28d
FDA approves first new UTI drug in decades
The drug is effective against UTIs caused by E. coli, klebsiella, Citrobacter freundii, Staphylococcus saprophyticus and Enterococcus faecalis. The most common side effects reported from using the ...
The Independent28d
FDA approves new UTI antibiotic that may help patients with recurring infections
coli, Klebsiella pneumoniae, Citrobacter freundii complex, Enterococcus faecalis, and a type of staph infection known as Staphylococcus saprophyticus. “The approval of Blujepa is a crucial ...
timesnownews28d
FDA Approves New Oral Antibiotic Blujepa For UTI Treatment In Women And Teens
The U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a novel oral antibiotic, for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women and children ...
Yahoo Finance29d
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Cassava Sciences, Inc SAVA nosedived following the failure of a late-stage study, while ...
Pharmaceutical Technology29d
FDA approves GSK’s Blujepa for uncomplicated UTIs
The approval is indicated for children aged 12 years and above. It is for uUTIs caused by susceptible micro-organisms such as Escherichia coli, Citrobacter freundii complex, Enterococcus faecalis, ...
BioPharma Dive29d
FDA approves first-of-its-kind antibiotic from GSK
It’s cleared to treat infections caused by E. coli as well as Staphylococcus saprophyticus, Klebsiella pneumoniae, Citrobacter freundii complex and Enterococcus faecalis. The drug has also shown ...
U.S. News & World Report29d
FDA Approves Blujepa for Uncomplicated Urinary Tract Infections
Blujepa, a first-in-class oral antibiotic, is approved for treatment of uUTIs caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus ...
FiercePharma29d
GSK ushers in new UTI antibiotic with FDA nod for first-in-class Blujepa
coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus or Enterococcus faecalis in women 12 years of age and older. These types of UTIs are the most common ...